|

The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center

RECRUITINGSponsored by The First Affiliated Hospital of Soochow University
Actively Recruiting
SponsorThe First Affiliated Hospital of Soochow University
Started2025-05-01
Est. completion2027-05-01
Eligibility
Age20 Years – 90 Years
SexMALE
Healthy vol.Accepted

Summary

The goal of this clinical trial aims to explore the diagnostic efficacy and grading of prostate cancer by a novel MRI sequences such as MAGiC,OGSE,CEST,IVIM,etc.The main question it aims to answer is: Can the novel non-contrast multiparametric MRI imaging improve the accuracy of diagnosis and grading of prostate cancer? For patients with clinical suspicion of prostate cancer, both conventional and new sequences magnetic resonance scans are conducted, with surgical or biopsy pathological results serving as the gold standard.

Eligibility

Age: 20 Years – 90 YearsSex: MALEHealthy volunteers accepted
Inclusion Criteria:

1. Patients with a high clinical suspicion of prostate cancer and elevated tPSA levels;
2. Patients with no prior history of other tumors;
3. Patients with no contraindications to MRI, including claustrophobia, presence of pacemakers, cardiac stents, or metal implants such as screws and plates.

Exclusion Criteria:

1. The patient has a history of malignant tumors and has received corresponding treatment;
2. Prior to the MRI examination, the patient has undergone treatment for prostate cancer, including endocrine therapy, radiotherapy, etc.;
3. Patients who have previously undergone radical prostatectomy for prostate cancer.

Conditions3

CancerProstate CancerProstate Cancer (Diagnosis)

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.